Clinical Trials Sponsored by Ono Pharma USA Inc

Total 212 results

Astellas Pharma Inc
Ono Pharma USA Inc

Completed

A Study to Evaluate Food Effect on ONO-5920/YM529 Intermittent Formulation

Bone Diseases | Osteoporosis | Osteoporosis, Postmenopausal

Japan
Ono Pharma USA Inc

Completed

Placebo-Controlled Study of ONO-2333Ms in Patients With Recurrent Major Depressive Disorder

Major Depressive Disorder

United States
Ono Pharma USA Inc

Terminated

A Study of the Safety and Efficacy of ONO-7746 in Adult Cancer Patients With Chemotherapy Induced Thrombocytopenia

Chemotherapy-Induced Thrombocytopenia

United States, Korea, Republic of, Russian Federation
Ono Pharma USA Inc
Ono Pharmaceutical Co. Ltd

Completed

ONO-2952 Single-dose PET Study in Healthy Adult Subjects

Healthy Adult Subjects

United States
Ono Pharma USA Inc

Completed

Controlled Study of ONO-1101 in Patients With Postoperative Tachyarrhythmias in Japan

Postoperative Supraventricular Tachyarrythmia
Ono Pharma USA Inc

Completed

Single Dose Escalation Study of ONO-9054 in Healthy Volunteers

Healthy Adult Subjects

United States
Ono Pharma USA Inc

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ONO-6950 in Healthy Adult Subjects

Healthy Adult Subjects

United States
Ono Pharma USA Inc

Terminated

Study to Evaluate the Effects of ONO-2952 on Pain Perception Produced by Rectal Distention in Female Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) (RESTORE)

Irritable Bowel Syndrome (IBS)

United States
Ono Pharma USA Inc
Ono Pharmaceutical Co. Ltd

Completed

A Placebo and Active Controlled Study of ONO-6950 in Asthmatic Patients

Asthma

United States
Ono Pharma USA Inc
Ono Pharmaceutical Co. Ltd

Completed

A Placebo and Active Controlled Study of ONO-6950 Following Allergen Challenge in Patients With Asthma

Asthma

Canada
Ono Pharma USA Inc

Completed

A Phase II Study to Evaluate the Effects of Oral ONO-5129 in Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

United States
Ono Pharma USA Inc

Completed

Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ONO-2952 in Healthy Adult Subjects

Healthy

United States
Ono Pharma USA Inc

Completed

Controlled Study of ONO-5334 in Postmenopausal Women With Osteopenia or Osteoporosis

Osteoporosis | Osteopenia

Netherlands
Ono Pharma USA Inc

Completed

A Phase 2, Multi-center Study to Evaluate the Efficacy and Safety of ONO-2952 in Female Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) (RESTORE)

Irritable Bowel Syndrome (IBS)

United States
Ono Pharma USA Inc

Completed

A Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis (DreaMS)

Multiple Sclerosis

United States, Belgium, Canada, Czech Republic, Germany, Greece, Japan, Poland, Russian Federation, Spain, Ukraine
Ono Pharma USA Inc
Ono Pharmaceutical Co. Ltd

Completed

An Open-label, Single-dose, Intravenous Administration Study of ONO-2745/CNS 7056 in Subjects With Chronic Hepatic Impairment

Healthy | Hepatic Impairment

United States
Ono Pharma USA Inc

Completed

Single and Multiple Dose Escalation and Two-sequence Crossover Study of ONO-9054 in Patients With Ocular Hypertension or Mild Open-angle Glaucoma

Ocular Hypertension (OHT) | Mild Open Angle-glaucoma (OAG)

United States
Ono Pharma USA Inc

Terminated

A Study to Evaluate the Effects of ONO-2506 Intravenous Infusion in Patients With Acute Ischemic Stroke

Cerebrovascular Accident

United States, Canada
Ono Pharma USA Inc

Completed

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ONO-6950 in Healthy Adult Subjects

Healthy Adult Subjects

United States
Ono Pharma USA Inc

Completed

Pilot Study of ONO-5129 in Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Japan
Ono Pharma USA Inc

Completed

Effects of ONO-2506PO in Patients With Alzheimer's Disease

Alzheimer's Disease

United States, Canada
Ono Pharma USA Inc

Completed

Single-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ONO-2952 in Healthy Adult Subjects

Healthy Adult Subjects

United States
Bristol-Myers Squibb
Ono Pharma USA Inc

Completed

BMS-936558 (MDX-1106) In Subjects With Advanced/Metastatic Clear-Cell Renal Cell Carcinoma (RCC)

Renal Cell Carcinoma

United States, Canada, Italy, Finland
Bristol-Myers Squibb
Ono Pharma USA Inc

Completed

Phase I Biomarker Study (BMS-936558)

Renal Cell Carcinoma

United States, France, Spain
Bristol-Myers Squibb
Ono Pharma USA Inc

Completed

Safety and Effectiveness of Nivolumab in Recurring Kidney Cancer Participants

Kidney Cancer | Renal Cancer

Japan
Bristol-Myers Squibb
Ono Pharma USA Inc

Completed

A Study of Effectiveness and Safety of the First-Line Nivolumab Plus Ipilimumab With or Without Chemotherapy for Advanced/Recurrent Non-Small Cell Lung Cancer in Japan (LIGHT-NING)

Non-Small Cell Lung Cancer

Japan
Bristol-Myers Squibb
Ono Pharma USA Inc

Completed

Effectiveness and Safety of Nivolumab in Participants That Have Head and Neck Cancer That Has Come Back or Has Spread

Cancer of Head and Neck | Cancer of the Head | Cancer of the Neck

Japan
Bristol-Myers Squibb
Medarex; Ono Pharma USA Inc

Completed

Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma

Malignant Melanoma

United States
Teikoku Pharma USA, Inc.

Recruiting

Evaluation of the Dexmedetomidine Transdermal Systems for Postoperative Analgesia Following Abdominoplasty (DMT2111)

Pain, Postoperative

United States
Meiji Pharma USA Inc.

Completed

Efficacy and Safety of ME3183 in Subjects With Moderate to Severe Plaque Psoriasis

Plaque Psoriasis

United States, Canada
Horizon Pharma USA, Inc.

Completed

Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical Study (OPTIC)

Thyroid Eye Disease | Graves' Orbitopathy

United States, Italy, Germany
Horizon Pharma USA, Inc.

Completed

Treatment of Graves' Orbitopathy to Reduce Proptosis With Teprotumumab Infusions in an Open-Label Clinical Extension Study (OPTIC-X)

Thyroid Eye Disease

Italy, United States, Germany
Teikoku Pharma USA, Inc.

Unknown

Evaluating Efficacy of the Dexmedetomidine Transdermal System for Postoperative Analgesia Following Abdominoplasty

Pain, Postoperative

United States
Fidia Pharma USA Inc.

Completed

2 Weekly Intra-articular Hyaluronan Knee Injections, Given 1 wk. Apart, of HYMOVIS Combined With Physical Exercise Program (PEP) Compared to PEP Alone, in Relatively Young, Active Population of Subjects With Patellofemoral Osteoarthritis (PFOA) and/or Tibiofemoral Osteoarthritis (TFOA)

Knee Osteoarthritis | Osteoarthritis, Knee | Patellofemoral Osteoarthritis

United States
Horizon Pharma USA, Inc.

Approved for marketing

Expanded Access Protocol of Teprotumumab (HZN-001) for Patients With Active Thyroid Eye Disease (EAP)

Thyroid Eye Disease | Graves' Orbitopathy

United States
Horizon Pharma USA, Inc.

Completed

Open-Label, Safety and Superior Effectiveness Study of Cysteamine Bitartrate Delayed-Release Capsules (RP103) in Cystinosis

Cystinosis

France, United States, United Kingdom, Belgium, Italy, Netherlands
Horizon Pharma USA, Inc.

Completed

Long-Term Safety Follow-up Study of Cysteamine Bitartrate Delayed-release Capsules (RP103)

Cystinosis

France, United States, Netherlands
Horizon Pharma USA, Inc.

Terminated

A Long-term Extension of Study RP103-MITO-001 (NCT02023866) to Assess Cysteamine Bitartrate Delayed-release Capsules (RP103) in Children With Inherited Mitochondrial Disease

Mitochondrial Diseases

United States
Horizon Pharma USA, Inc.

Completed

"Safety, Tolerability and Pharmacokinetics of MP-376 Administered for 14 Days to Stable Pediatric (CF) Patients"

Cystic Fibrosis

United States
Horizon Pharma USA, Inc.

Completed

A Phase 2 Study of MP-376 to Prevent Acute Exacerbations in Chronic Obstructive Pulmonary Disease (COPD) Patients

Chronic Obstructive Pulmonary Disease

United States
Horizon Pharma USA, Inc.

Completed

Phase 3 Study of Cysteamine Bitartrate Delayed-release (RP103) Compared to Cystagon® in Patients With Cystinosis

Cystinosis

France, United States, Netherlands
Horizon Pharma USA, Inc.

Completed

Pilot Study of Safety, Tolerability, Pharmacokinetics/Pharmacodynamics of RP103 Compared to Cystagon® in Patients With Cystinosis

Cystinosis

United States
Teikoku Pharma USA, Inc.

Not yet recruiting

Dexmedetomidine Transdermal Systems (DMTS) Treatment for Agitation Associated With Dementia of the Alzheimer's Type

Agitation
Horizon Pharma USA, Inc.

Completed

Safety/Effectiveness Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) in Cysteamine Treatment Naive Patients With Cystinosis

Cystinosis

United States, Brazil
Horizon Pharma USA, Inc.

Completed

A Phase 1b Study to Evaluate the Safety and PK of MP-376 in Chronic Obstructive Pulmonary Disease (COPD) Patients

Chronic Obstructive Pulmonary Disease

United States
Horizon Pharma USA, Inc.

Completed

Phase IIa Study of Fomepizole for Acetaldehyde Toxicity After Ethanol Exposure in Subjects With Altered Ethanol Metabolism

Aldehyde Dehydrogenase-2 (ALDH2) Deficiency

United States
Horizon Pharma USA, Inc.

Recruiting

A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active Thyroid Eye Disease

Thyroid Eye Disease

United States
Teikoku Pharma USA, Inc.

Completed

Study in Elderly Alzheimer's Patients to Assess Skin Tolerability, Irritation With 3, 7-Day Applications of DTP-System (DTP-System)

Irritation/Irritant

United States
Horizon Pharma USA, Inc.

Completed

Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease

Thyroid-Associated Ophthalmopathy | Thyroid Associated Ophthalmopathies

United Kingdom, United States, Germany, Italy
Horizon Pharma USA, Inc.

Completed

Safety, Tolerability and Efficacy of MP-376 Given for 28 Days to Cystic Fibrosis (CF) Patients

Cystic Fibrosis (CF)

Germany, United States, Netherlands

3

Subscribe